The discovery of the EWSR1-PSMC5 fusion gene in chemotherapy-resistant osteosarcoma presents a potential biomarker for predicting treatment responses, thereby facilitating personalized medicine approaches. The gene discussed is PSMC5; the disease is osteosarcoma.